Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 12470755)

Published in Am J Ophthalmol on December 01, 2002

Authors

Henry D Jampel1, Jason Bacharach, Wang-Pui Sheu, Lisa G Wohl, Alfred M Solish, William Christie, Latanoprost/Unoprostone Study Group

Author Affiliations

1: Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9205, USA. hjampel@jhmi.edu

Articles by these authors

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol (2003) 4.35

Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology (2004) 1.29

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma (2005) 1.17

Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther (2004) 0.95

Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma (2005) 0.78

Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina (2016) 0.77

Efficacy of trabecular bypass stent through 2 years: data from the United States pivotal trial. J Cataract Refract Surg (2014) 0.76

A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. BMC Ophthalmol (2011) 0.75

Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol (2003) 0.75

The current state of corneal reshaping. Eye Contact Lens (2005) 0.75